Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
Monte Rosa Therapeutics reported positive Phase 1 GFORCE-1 results for MRT-8102, a NEK7-directed molecular glue degrader, in 108 obese subjects with elevated cardiovascular risk. NEK7 degradation was robust and sustained (~80-90% median) across all doses, with key ASCVD biomarkers (calprotectin -56%, SAA -51%, hsCRP -85%) normalized to healthy-volunteer levels and lipoprotein(a) reduced 24%, comparable to PCSK9 inhibitors. The drug was well tolerated with no serious adverse events and TEAE rates similar to placebo (33% vs 30%).
Key figures
- Drug Name
- MRT-8102
- Phase Of Trial
- Phase 1
- Il6 reduction
- 54%
- Lpa reduction
- 24%
- Saa reduction
- 51%
- Hscrp reduction
- 85%
- S100a12 reduction
- 46%
- Subjects enrolled
- 108
- Teae rate mrt8102
- 33%
- Teae rate placebo
- 30%
- Fibrinogen reduction
- 28%
- Calprotectin reduction
- 56%
- Nek7 degradation median
- 80-90%
- Il1b reduction top quartile
- 37%
- Hmgb1 reduction top quartile
- 40%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.